Baseline characteristics

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma · Source last updated 2023-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      8

   2. group Id

      BG001

      value

      13

   3. group Id

      BG002

      value

      21

   units

   Participants

groups

1. description

   Participants with non-follicular iNHL with MZL as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.

   id

   BG000

   title

   MZL: Umbralisib

2. description

   Participants with non-follicular iNHL with WM as the histology type received umbralisib, 800 mg, orally, QD, until disease progression, unacceptable toxicity, or withdrawal from the study whichever occurred first.

   id

   BG001

   title

   WM: Umbralisib

3. description

   Total of all reporting groups

   id

   BG002

   title

   Total

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            spread

            7.64

            value

            71.9

         2. group Id

            BG001

            spread

            5.78

            value

            67.7

         3. group Id

            BG002

            spread

            6.69

            value

            69.3

   dispersion Type

   STANDARD_DEVIATION

   param Type

   MEAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            4

         2. group Id

            BG001

            value

            6

         3. group Id

            BG002

            value

            10

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            4

         2. group Id

            BG001

            value

            7

         3. group Id

            BG002

            value

            11

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            6

         2. group Id

            BG001

            value

            11

         3. group Id

            BG002

            value

            17

      title

      White

   2. categories

      1. measurements

         1. group Id

            BG000

            value

            1

         2. group Id

            BG001

            value

            1

         3. group Id

            BG002

            value

            2

      title

      Black or African American

   3. categories

      1. measurements

         1. group Id

            BG000

            value

            1

         2. group Id

            BG001

            value

            0

         3. group Id

            BG002

            value

            1

      title

      Asian

   4. categories

      1. measurements

         1. group Id

            BG000

            value

            0

         2. group Id

            BG001

            value

            1

         3. group Id

            BG002

            value

            1

      title

      Other

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Race/Ethnicity, Customized

   unit Of Measure

   Participants

population Description

Safety population included all enrolled participants who received at least one dose of study treatment.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice